Industry News

• Funds awarded for disease demonstration studies and technology development   The NIH has awarded $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease. The funds will support investigators to develop innovative technologies to improve identification and characterization of the human microbiome.
  National Institutes of Health September 08, 2010  
• Emergent announces early termination of HSR waiting peiod for Trubion acquisition  Emergent announced the U.S. Department of Justice and FTC granted early termination of the waiting period with respect to their acquisition of Trubion Pharmaceuticals announced August 12, 2010. The closing of the transaction remains subject to approval by Trubion's stockholders.
  Emergent BioSolutions Inc. September 08, 2010  
• New patient safety alliance launches tools to fight pain medication misuse and abuse  The C.A.R.E.S. Alliance, a new patient safety organization, launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications.
  Covidien September 08, 2010  
• Emergent announces phase I trial for monoclonal antibody to treat inhalational anthrax   Emergent BioSolutions announced that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced. Emergent’s fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
  Emergent BioSolutions Inc. September 08, 2010  
• Abbott completes acquisition of India's Piramal Healthcare Solutions business  Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian market and further accelerating the company's growth in emerging markets. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020.
  Abbott September 08, 2010  
• Targeted drug for melanoma shows promise in early clinical testing  The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers announced last month.
  National Cancer Institute September 07, 2010  
• Bristol-Myers Squibb announces dividend  The Board of Directors of Bristol-Myers Squibb declared a quarterly dividend of 32 cents ($0.32) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 1, 2010 to stockholders of record at the close of business on October 1, 2010.
  Bristol-Myers Squibb Company September 07, 2010  
• Oxygen Biotherapeutics TBI Study to be offered to injured Israeli  Oxygen Biotherapeutics announced that Israeli soldiers who suffer severe traumatic brain injury can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel. The company expects to reconvene enrollment after the required regulatory adjustments have been approved.
  Oxygen Biotherapeutics, Inc. September 07, 2010  Oxygen Biotherapeutics, Inc.
• PPD Establishes network of sites for conducting phase I trials in patients  PPD announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services, including Commonwealth Biomedical Research, CNS Network and Lovelace Scientific Resources.
  PPD, Inc. September 07, 2010  
• FDA advisory committee recommends approval of Forest Laboratories' Ceftaroline Fosamil   Forest Laboratories announced the FDA Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0in favor of approval for complicated skin and skin structure infections.
  Forest Laboratories, Inc. September 07, 2010  

   (next 10 articles)